Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF

Experimental Neurology

Volumn 181, Issue 2, 2003, Pages 213-223

  McBride, Jodi L ^a   During, Matthew J ^b,c   Wuu, Joanne ^a   Chen, Er Yun ^a   Leurgans, Sue E ^a   Kordower, Jeffrey H ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

3 Nitropropionic acid; Adenoassociated viral vector; Gene therapy; Glial cell line derived neurotrophic factor; Huntington's disease; Rat

Indexed keywords

3 NITROPROPIONIC ACID; ADENOSINE 3'5' MONOPHOSPHATE REGULATED PHOSPHOPROTEIN; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GREEN FLUORESCENT PROTEIN; PROTEIN; TOXIN; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TESTING ALTERNATIVE; ANIMAL TISSUE; ARTICLE; BRAIN FUNCTION; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; DATA ANALYSIS; GENE TRANSFER; HISTOLOGY; HUNTINGTON CHOREA; IMMUNOREACTIVITY; INJECTION; MALE; MITOCHONDRION; NERVE CELL; NEUROANATOMY; NEUROLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SCALE UP; SCORING SYSTEM; STAINING; TASK PERFORMANCE; VIRAL GENETICS;

EID: 0037762555     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4886(03)00044-X     Document Type: Article

References (31)

1. Araujo D.M., Hilt D.C. Glial cell line-derived neurotrophic factor attenuates the exitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington's disease. Neuroscience. 81:1997;1099-1110.
2. Araujo D.M., Hilt D.C. Glial cell line-derived neurotrophic factor attenuates the locomotor hypofunction and striatonigral neurochemical deficits induced by chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid. Neuroscience. 82:1998;117-127.
3. Auerbach W., Hurlbert M.S., Hilditch-Maguire P., Wadghiri Y.Z., Wheeler V.C., Cohen S.I., Joyner A.L., MacDonald M.E., Turnbull D.H. The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. Hum. Mol. Genet. 10:2001;2515-2523.
4. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13:1993;4181-4192.
5. Bjorklund A., Kirik D., Rosenblad C., Georgieyska B., Lundberg C., Mandel R.J. Towards a neuroprotective gene therapy for Parkinson's disease use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model . Brain Res. 886:2000;82-98.
6. Blum D., Gall D., Cuvelier L., Schiffmann S. Topological analysis of striatal lesions induced by 3-nitroproprionic acid in the Lewis rat. Neuroreport. 12:2001;1769-1772.
7. Brouillet E., Conde F., Beal M.F., Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 59:1999;427-468.
8. Cao L., Liu Y., During M.J., Xiao W. High-titer, wild-type free recombinant adeno-associated virus vector production using intron-containing helper plasmids. J. Virol. 74:2000;11456-11463.
9. Conneally P.M., Wallace M.R., Gusella J.F., Wexler N.S. Huntington's disease estimation of heterozygote status using linked genetic markers . Genet. Epidemiol. 1:1984;81-88.
10. Davies S.W., Beardsall K. Nerve growth factor selectively prevents excitotoxin-induced degeneration of striatal cholinergic neurones. Neurosci. Lett. 140:1992;161-164.
11. de Almeida L.P., Zala D., Aebischer P., Deglon N. Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiol. Dis. 8:2001;433-446.
12. El Massioui N., Ouary S., Cheruel F., Hantraye P., Brouillet E. Perseverative behavior underlying attentional set-shifting deficits in rats chronically treated with the neurotoxin 3-nitroproprionic acid. Exp. Neurol. 172:2001;172-181.
13. Gratacos E., Perez-Navarro E., Tolosa E., Arenas E., Alberch J. Neuroprotection of striatal neurons against kainate excitotoxicity by neurotrophins and GDNF family members. J. Neurochem. 78:2001;1287-1296.
14. Guyot M.C., Hantraye P., Dolan R., Palfi S., Maziere M., Brouillet E. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience. 79:1997;45-56.
15. Guyot M.C., Palfi S., Stutzmann J.M., Maziere M., Hantraye P., Brouillet E. Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats. Neuroscience. 81:1997;141-149.
16. Kaplitt M.G., Leone P., Samulski R.J., Xiao X., Pfaff D.W., O'Malley K.L., During M.J. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. 8:1994;148-154.
17. Kaspar B., Vissel B., Bengoechea T., Crone S., Randolph-Moore L., Muller R., Brandon E.P., Schaffer D., Verma I.M., Lee K.F., Heinemann S.F., Gage F.H. Adeno-associated virus effectively mediates conditional gene modification in the brain. Proc. Natl. Acad. Sci. USA. 99:2002;2320-2325.
18. Kodsi M.H., Swerdlow N.R. Mitochondrial toxin 3-nitroproprionic acid produces startle reflex abnormalities and striatal damage in rats that model some features of Huntington's disease. Neurosci. Lett. 231:1997;103-107.
19. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Deglon N., Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science. 290:2000;767-773.
20. Ludolph A.C., He F., Spencer P.S., Hammerstad J., Sabri M. 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can. J. Neurol. Sci. 18:1991;492-498.
21. Muramatsu S., Fujimoto K., Ikeguchi K., Shizuma N., Kawasaki K., Ono F., Shen Y., Wang L., Mizukami H., Kume A., Matsumura M., Nagatsu I., Urano F., Ichinose H., Nagatsu T., Terao K., Nakano I., Ozawa K. Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum. Gene Ther. 13:2002;345-354.
22. Ouary S., Bizat N., Altairac S., Ménétrat H., Mittoux V., Condé F., Hantraye P., Brouillet E. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitroproprionic acid in rats implications for neuroprotection studies . Neuroscience. 97:2000;521-530.
23. Palfi S., Leventhal L., Goetz C.G., Hantraye T., Roitberg B.Z., Sramek J., Emborg M., Kordower J.H. Delayed onset of progressive dystonia following subacute 3-nitropropionic acid treatment in Cebus apella monkeys. Mov. Disord. 15:2000;524-530.
24. Perez-Navarro E., Arenas E., Reiriz J., Calvo N., Alberch J. Glial cell line-derived neurotrophic factor protects striatal calbindin-immunoreactive neurons from exitotoxic damage. Neuroscience. 75:1996;345-352.
25. Perez-Navarro E., Arenas E., Marco S., Alberch J. Intrastriatal grafting of a GDNF-producing cell line protects striatonigral neurons from quinolinic acid excitotoxicity in vivo. Eur. J. Neurosci. 11:1999;241-249.
26. Sanberg P.R., Wictorin K., Isacson O. Cell Transplantation for Huntington's Disease. 1994;R.G Landes, Austin, TX.
27. Shear D.A., Haik K.L., Dunbar G.L. Creatine reduces 3-nitropropionic-acid-induced cognitive and motor abnormalities in rats. Neuroreport. 11:2000;1833-1837.
28. Vonsattel J.P., Myers R.H., Stevens T.J. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44:1985;559-577.
29. West M.J., Ostergaard K., Andreassen O.A., Finsen B. Estimation of the number of somatostatin neurons in the striatum an in situ hybridization study using the optical fractionator method . J. Comp. Neurol. 370:1996;11-22.
30. Xu R., Janson C.G., Mastakov M., Lawlor P., Young D., Mouravlev A., Fitzsimons H., Choi K.L., Ma H., Dragunow M., Leone P., Chen Q., Dicker B., During M.J. Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes. Gene Ther. 8:2001;1323-1332.
31. Zeger S.L., Liang K.Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 42:1986;121-130.